.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for inclusion of individuals along with MASLD as well as measurement of liver outcomes in cardio-- kidney-- metabolic trials, when information suggest mechanistically probable benefits as well as clinical safety and security-- and summarizes points to consider for test concept and also regulatory commendation.